Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.66 |
| ▸ | BCR | P11274 | 12/20 | 0.66 |
| ▸ | PRKCA | P17252 | 6/20 | 0.66 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364396 | 0.93 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL1550 | 0.93 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| Water SCHEMBL28827802 | 0.92 | ABL1 (0.68) | ABL1BCRPRKCAEGFRSRC | |
| Alcohol SCHEMBL28827807 | 0.88 | ABL1 (0.63) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3861941 | 0.86 | ABL1 (0.69) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL13899260 | 0.84 | ABL1 (0.67) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL14763670 | 0.84 | ABL1 (0.61) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL3864409 | 0.84 | ABL1 (0.66) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL20237243 | 0.83 | ABL1 (0.57) | ABL1BCRPRKCAEGFRSRC | |
| SCHEMBL14938216 | 0.83 | ABL1 (0.85) | ABL1BCRPRKCAEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130121963-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20100221221-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130121963-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | NME2, NME1, ABL1 | ABL1 3/4885BCR 841/4885PRKCA 312/4885 |
| US-20100221221-A1 | N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES | NME2, NME1, ABL1 | ABL1 3/4885BCR 841/4885PRKCA 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.